Skip to main content

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 3 of 12

  1. Metastasis is a leading cause of breast cancer mortality. The induction of epithelial-to-mesenchymal transition (EMT) and complex oncogenic signaling is a vital step in the evolution of highly metastatic and t...

    Authors: Jia-Hong Chen, Wen-Chien Huang, Oluwaseun Adebayo Bamodu, Peter Mu-Hsin Chang, Tsu-Yi Chao and Tse-Hung Huang

    Citation: BMC Cancer 2019 19:634

    Content type: Research article

    Published on:

  2. Malignant pleural effusion (MPE) is a devastating sequela associated with cancer. Talc pleurodesis is a common treatment strategy for MPE but has been estimated to be unsuccessful in up to 20–50% of patients. ...

    Authors: Tim N. Beck, Alexander Y. Deneka, Louis Chai, Colin Kanach, Priya Johal, Nicolas J. Alvarez, Yanis Boumber, Erica A. Golemis and Glenn W. Laub

    Citation: BMC Cancer 2019 19:614

    Content type: Research article

    Published on:

  3. Podoplanin (PDPN), a transmembrane O-glycoprotein, is up-regulated in many tumors and is involved in tumor metastasis and malignant progression. In previous studies, we generated a functional blocking monoclonal ...

    Authors: Mengqiao Xu, Xia Wang, Yanfang Pan, Xingpeng Zhao, Bin Yan, Changgeng Ruan, Lijun Xia and Yiming Zhao

    Citation: BMC Cancer 2019 19:599

    Content type: Research article

    Published on:

  4. Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall surv...

    Authors: Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux and Jonathan Wadsley

    Citation: BMC Cancer 2019 19:582

    Content type: Study protocol

    Published on:

  5. Molecular markers predicting survival in esophageal adenocarcinoma (EAC) are rare. Specifically, in favorable oncologic situations, e.g. nodal negativity or major neoadjuvant therapy response, there is a lack ...

    Authors: Lars M. Schiffmann, Heike Göbel, Heike Löser, Fabian Schorn, Jan Paul Werthenbach, Hans F. Fuchs, Patrick S. Plum, Marc Bludau, Thomas Zander, Wolfgang Schröder, Christiane J. Bruns, Hamid Kashkar, Alexander Quaas and Florian Gebauer

    Citation: BMC Cancer 2019 19:531

    Content type: Research article

    Published on:

  6. The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these...

    Authors: Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris III, Sven Stanzel, Monika Patre and Paul Anthony Ellis

    Citation: BMC Cancer 2019 19:517

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2019 19:620

  7. Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by long-term human T-cell leukemia virus type I (HTLV-1) infection. Survivin-responsive, conditionally replicating adenoviruses reg...

    Authors: Shinsuke Suzuki, Hiroki Kofune, Kimiharu Uozumi, Makoto Yoshimitsu, Naomichi Arima, Kenji Ishitsuka, Shin-ichi Ueno and Ken-ichiro Kosai

    Citation: BMC Cancer 2019 19:516

    Content type: Research article

    Published on:

  9. Liposarcoma (LPS) is a tumor derived from adipose tissue, and has the highest incidence among soft tissue sarcomas. Dedifferentiated liposarcoma (DDLPS) is a malignant tumor with poor prognosis. Recurrence and...

    Authors: Eun Byeol Jo, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Hyojun Park, Yoon-La Choi, Doopyo Hong and Sung Joo Kim

    Citation: BMC Cancer 2019 19:496

    Content type: Research article

    Published on:

  10. Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain...

    Authors: Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios and André Fay

    Citation: BMC Cancer 2019 19:487

    Content type: Study protocol

    Published on:

  12. While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic ...

    Authors: Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro, Hildur Helgadottir, Ingrid Ljuslinder, Max Levin, Charlotta All-Eriksson, Bengt Andersson, Ulrika Stierner, Lisa M. Nilsson, Jonas A. Nilsson and Lars Ny

    Citation: BMC Cancer 2019 19:415

    Content type: Study protocol

    Published on:

  13. Previous work in our laboratory demonstrated that antiprogestin mifepristone impairs the growth and adhesion of highly metastatic cancer cells, and causes changes in their cellular morphology. In this study, w...

    Authors: Sabrina J. Ritch, BreeAnn N. Brandhagen, Alicia A. Goyeneche and Carlos M. Telleria

    Citation: BMC Cancer 2019 19:376

    Content type: Technical advance

    Published on:

  14. Head and neck squamous cell carcinoma (HNSCC) represents one of the most common malignancies worldwide with a high mortality rate mainly due to lack of early detection markers, frequent association with metast...

    Authors: Subhayan Sur, Hiroshi Nakanishi, Robert Steele and Ratna B. Ray

    Citation: BMC Cancer 2019 19:354

    Content type: Research article

    Published on:

  15. Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more ag...

    Authors: Lana McClements, Stephanie Annett, Anita Yakkundi, Martin O’Rourke, Andrea Valentine, Nermeen Moustafa, Abdelrahim Alqudah, Bruno M. Simões, Fiona Furlong, Amy Short, Stuart A. McIntosh, Helen O. McCarthy, Robert B. Clarke and Tracy Robson

    Citation: BMC Cancer 2019 19:351

    Content type: Research article

    Published on:

  16. The exact signalling mechanism of the mTOR complex remains a subject of constant debate, even with some evidence that amino acids participate in the same pathway as used for insulin signalling during protein s...

    Authors: Bread Cruz, André Oliveira, Gislaine Ventrucci and Maria Cristina Cintra Gomes-Marcondes

    Citation: BMC Cancer 2019 19:349

    Content type: Research article

    Published on:

  17. Most tumor cells show aberrantly activated Akt which leads to increased cell survival and resistance to cancer radiotherapy. Therefore, targeting Akt can be a promising strategy for radiosensitization. Here, w...

    Authors: Cholpon S. Djuzenova, Vanessa Fiedler, Simon Memmel, Astrid Katzer, Dmitri Sisario, Philippa K. Brosch, Alexander Göhrung, Svenja Frister, Heiko Zimmermann, Michael Flentje and Vladimir L. Sukhorukov

    Citation: BMC Cancer 2019 19:299

    Content type: Research article

    Published on:

  18. With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the saf...

    Authors: Ying Fan, Shu Li, Xiaoyan Ding, Jian Yue, Jun Jiang, Hong Zhao, Rui Hao, Weiliang Qiu, Kezhen Liu, Ying Li, Shengdian Wang, Limin Zheng, Bin Ye, Kun Meng and Binghe Xu

    Citation: BMC Cancer 2019 19:279

    Content type: Research article

    Published on:

  19. Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed ...

    Authors: Melanie F. Pradier, Bernhard Reis, Lori Jukofsky, Francesca Milletti, Toshihiko Ohtomo, Fernando Perez-Cruz and Oscar Puig

    Citation: BMC Cancer 2019 19:278

    Content type: Research article

    Published on:

  20. Recent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease. However, an un-met clinical need remains in B-Raf inhibitor resist...

    Authors: Connor M. Blair, Nicola M. Walsh, Bruce H. Littman, Frank W. Marcoux and George S. Baillie

    Citation: BMC Cancer 2019 19:266

    Content type: Research article

    Published on:

  21. Epithelial-mesenchymal transition (EMT) may be one of the reasons for the failure in some clinical trials regarding histone deacetylase inhibitors (HDACIs)-treated solid tumors. We investigated the effects of ...

    Authors: Zhihua Shen, Xiaomin Liao, Zhongming Shao, Muyin Feng, Jianling Yuan, Sisi Wang, Siyuan Gan, Yanping Ha, Zhiwei He and Wei Jie

    Citation: BMC Cancer 2019 19:262

    Content type: Research article

    Published on:

  22. Garlic has been used for centuries for its flavour and health promoting properties that include protection against cancer. The vinyl disulfide-sulfoxide ajoene is one of the phytochemicals found in crushed clo...

    Authors: Catherine H. Kaschula, Rosanna Tuveri, Ellen Ngarande, Kevin Dzobo, Christopher Barnett, Daniel A. Kusza, Lisa M. Graham, Arieh A. Katz, Mohamed Suhail Rafudeen, M. Iqbal Parker, Roger Hunter and Georgia Schäfer

    Citation: BMC Cancer 2019 19:248

    Content type: Research article

    Published on:

  23. High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 ...

    Authors: Stefanie Klenke, Neval Akdeli, Patrick Stelmach, Lukas Heukamp, Johannes H. Schulte and Hagen S. Bachmann

    Citation: BMC Cancer 2019 19:243

    Content type: Research article

    Published on:

  24. Patients with relapsed/refractory acute myeloid leukemia after hematopoietic stem cell transplantation (HSCT) have a poor prognosis, with a 2-year survival rate of 14%. The optimal treatment for these patients...

    Authors: Mengqi Jin, Yongxian Hu, Wenjun Wu, Yi Luo, Yamin Tan, Jian Yu, Aiyun Jin, Luxin Yang, He Huang and Guoqing Wei

    Citation: BMC Cancer 2019 19:242

    Content type: Case report

    Published on:

    The Correction to this article has been published in BMC Cancer 2019 19:486

  25. The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors including a subset of acute B-lymphoblastic leuk...

    Authors: Anna Richter, Catrin Roolf, Mohamed Hamed, Yvonne Saara Gladbach, Sina Sender, Christoph Konkolefski, Gudrun Knübel, Anett Sekora, Georg Fuellen, Brigitte Vollmar, Hugo Murua Escobar and Christian Junghanss

    Citation: BMC Cancer 2019 19:202

    Content type: Research article

    Published on:

  26. Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expre...

    Authors: Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng and Bhumsuk Keam

    Citation: BMC Cancer 2019 19:196

    Content type: Research article

    Published on:

  27. It has been demonstrated that relatively small variations of the parameters of exposure to extremely low frequency magnetic fields (ELF-MF) can change significantly the outcome of experiments. Hence, either in...

    Authors: Leonardo Makinistian, Eva Marková and Igor Belyaev

    Citation: BMC Cancer 2019 19:188

    Content type: Research article

    Published on:

  28. MicroRNAs are noncoding RNA molecules of ~ 22 nucleotides with diagnostic and therapeutic action [Curr Drug Targets, 2015. 16(12): p. 1381-403], affecting the expression of mRNAs involved in invasion, migratio...

    Authors: Olga D’Almeida, Omar Mothar, Esther Apraku Bondzie, Yolande Lieumo, Laure Tagne, Sumeet Gupta, Thomas Volkert, Stuart Levine and Jean-Bosco Tagne

    Citation: BMC Cancer 2019 19:136

    Content type: Research article

    Published on:

  29. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegyl...

    Authors: Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz and Ildiko Aradi

    Citation: BMC Cancer 2019 19:122

    Content type: Research article

    Published on:

  30. Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer) patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cance...

    Authors: Nuramalina H. Mumin, Neele Drobnitzky, Agata Patel, Luiza Madia Lourenco, Fiona F. Cahill, Yanyan Jiang, Anthony Kong and Anderson J. Ryan

    Citation: BMC Cancer 2019 19:102

    Content type: Research article

    Published on:

  31. Synthetic indolyl- pyridinyl- propenones (IPPs) induce methuosis, a form of non-apoptotic cell death, in glioblastoma and other cancer cell lines. Methuosis is characterized by accumulation of cytoplasmic vacu...

    Authors: Zehui Li, Nneka E. Mbah, Jean H. Overmeyer, Jeffrey G. Sarver, Sage George, Christopher J. Trabbic, Paul W. Erhardt and William A. Maltese

    Citation: BMC Cancer 2019 19:77

    Content type: Research article

    Published on:

  32. To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeuti...

    Authors: Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns and Thomas Thomaidis

    Citation: BMC Cancer 2019 19:55

    Content type: Research article

    Published on:

  33. Shikonin, a natural naphthoquinone, is abundant in Chinese herb medicine Zicao (purple gromwell) and has a wide range of biological activities, especially for cancer. Shikonin and its analogues have been repor...

    Authors: Shoude Zhang, Qiang Gao, Wei Li, Luwei Zhu, Qianhan Shang, Shuo Feng, Junmei Jia, Qiangqiang Jia, Shuo Shen and Zhanhai Su

    Citation: BMC Cancer 2019 19:20

    Content type: Research article

    Published on:

  34. A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysi...

    Authors: Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair and Brian I. Rini

    Citation: BMC Cancer 2019 19:17

    Content type: Research article

    Published on:

  35. Dung beetle glycosaminoglycan is known to possess anti-aging activities. However, its anti-cancer mechanisms are not fully elucidated yet. The objective of this study was to evaluate the anti-cancer effect of ...

    Authors: Mi Young Ahn, Ban Ji Kim, Ha Jeong Kim, Jang Mi Jin, Hyung Joo Yoon, Jae Sam Hwang and Kun-Koo Park

    Citation: BMC Cancer 2019 19:9

    Content type: Research article

    Published on:

  36. The GTPase KRas4B has been utilized as a principal target in the development of anticancer drugs. PDE6δ transports KRas4B to the plasma membrane, where it is released to activate various signaling pathways req...

    Authors: Diana Casique-Aguirre, Paola Briseño-Díaz, Ponciano García-Gutiérrez, Claudia Haydée González-de la Rosa, Reyna Sara Quintero-Barceinas, Arturo Rojo-Domínguez, Irene Vergara, Luis Alberto Medina, José Correa-Basurto, Martiniano Bello, Rosaura Hernández-Rivas, María del RocioThompson-Bonilla and Miguel Vargas

    Citation: BMC Cancer 2018 18:1299

    Content type: Research article

    Published on:

  37. HDIL-2 is approved for advanced melanoma based on its durable antitumor activity. MAGE-A3 cancer immunotherapeutic (MAGE-A3 CI) is a recombinant MAGE-A3 protein combined with an immunostimulant adjuvant system...

    Authors: Jennifer L. McQuade, Jade Homsi, Carlos A. Torres-Cabala, Roland Bassett, Rashmi Murthy Popuri, Marihella L. James, Luis M. Vence and Wen-Jen Hwu

    Citation: BMC Cancer 2018 18:1274

    Content type: Research article

    Published on:

  38. Brain tumor vasculature can be significantly compromised and leakier than that of normal brain blood vessels. Little is known if there are vascular permeability alterations in the brain adjacent to tumor (BAT)...

    Authors: Afroz S. Mohammad, Chris E. Adkins, Neal Shah, Rawaa Aljammal, Jessica I. G. Griffith, Rachel M. Tallman, Katherine L. Jarrell and Paul R. Lockman

    Citation: BMC Cancer 2018 18:1225

    Content type: Research article

    Published on:

  39. In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cy...

    Authors: Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco and Pier Francesco Bassi

    Citation: BMC Cancer 2018 18:1224

    Content type: Research article

    Published on:

  40. Agarose encapsulated murine renal adenocarcinoma cells (RENCA macrobeads) are currently being investigated in clinical trials as a treatment for therapy-resistant metastatic colorectal cancer. We have previous...

    Authors: Prithy C. Martis, Atira T. Dudley, Melissa A. Bemrose, Hunter L. Gazda, Barry H. Smith and Lawrence S. Gazda

    Citation: BMC Cancer 2018 18:1217

    Content type: Research article

    Published on:

  41. Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of G...

    Authors: Li Li, Yulun Huang, Yuge Gao, Tengfei Shi, Yunyun Xu, Huini Li, Marko Hyytiäinen, Jorma Keski-Oja, Qiuying Jiang, Yizhou Hu and Zhimin Du

    Citation: BMC Cancer 2018 18:1215

    Content type: Research article

    Published on:

  43. The nudix family member enzyme MutT homologue-1 (MTH1) hydrolyses the oxidized nucleotides 8-oxo-dGTP and 2-hydroxy-dATP and thus prevents the incorporation of damaged nucleotides into nuclear and mitochondria...

    Authors: Mosche Pompsch, Julia Vogel, Fabian Classen, Philip Kranz, George Iliakis, Helena Riffkin, Ulf Brockmeier and Eric Metzen

    Citation: BMC Cancer 2018 18:1190

    Content type: Research article

    Published on:

  44. Waixenicin A, a bioactive extract of soft coral Sarcothelia edmondsoni, has been shown to be anti-neoplastic. However, its mechanisms of action remain unclear. Cancer stem cells (CSCs) and associated stemness fac...

    Authors: Kai Liu, Shao-Hua Xu, Zhao Chen, Qing-Xin Zeng, Zhi-Jun Li and Zhou-Miao Chen

    Citation: BMC Cancer 2018 18:1167

    Content type: Research article

    Published on:

  45. Insulin resistance (IR) is closely associated with the progression of hepatocellular carcinoma (HCC). Acyclic retinoid (ACR) targets retinoid X receptor α and reportedly prevents HCC recurrence in clinical pra...

    Authors: Norihisa Nishimura, Kosuke Kaji, Mitsuteru Kitade, Yosuke Aihara, Shinya Sato, Kenichiro Seki, Yasuhiko Sawada, Hiroaki Takaya, Yasushi Okura, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Akira Mitoro and Hitoshi Yoshiji

    Citation: BMC Cancer 2018 18:1164

    Content type: Research article

    Published on:

  46. Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantat...

    Authors: Shupeng Wen, Zhiyun Niu, Lina Xing, Ying Wang, Hang Li, Na Kuang, Jianmin Luo, Xuejun Zhang and Fuxu Wang

    Citation: BMC Cancer 2018 18:1143

    Content type: Case report

    Published on:

  47. Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and the proteasome inhibitor bortezomib were investigated in DLBCL and mantle cell lymphoma cells (MCL).

    Authors: Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun and Steven Grant

    Citation: BMC Cancer 2018 18:1129

    Content type: Research article

    Published on:

  48. The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neut...

    Authors: Henri Roché, Jean-Christophe Eymard, Abderraouf Radji, Alain Prevost, Rafik Diab, Michele Lamuraglia, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau and Alain Toledano

    Citation: BMC Cancer 2018 18:1127

    Content type: Research article

    Published on:

  49. Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape o...

    Authors: Luca Bertamini, Jacopo Nanni, Giovanni Marconi, Mariachiara Abbenante, Valentina Robustelli, Francesco Bacci, Antonella Matti, Stefania Paolini, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefano De Polo, Michele Cavo, Antonio Curti, Giovanni Martinelli and Cristina Papayannidis

    Citation: BMC Cancer 2018 18:1117

    Content type: Case report

    Published on:

  50. To identify potential therapeutic target in clear cell renal cell carcinoma (ccRCC), we performed a transcriptome analysis. Our analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean di...

    Authors: Kazuhiro Nagao, Nachi Shinohara, Frank Smit, Mirjam de Weijert, Sander Jannink, Yuji Owada, Peter Mulders, Egbert Oosterwijk and Hideyasu Matsuyama

    Citation: BMC Cancer 2018 18:1114

    Content type: Research article

    Published on:

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us